In the Danish Biotech Weekly, we give you insights into the Danish biotech stocks. We follow the small and established ones at home and abroad. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets right issues, etc.
7 of the 20 listed, Danish biotech companies have published news the past week. 12 of the companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date.
Company news the past week
Ascendis Pharma
No news the past week
No news the past week
Cessatech
No news the past week
CS MEDICA A/S Announces “Proof of Concept” with Successful Clinical Trial Results of CANNASEN® Pain Patch (LINK)
CS MEDICA Greenlights Establishment of CANNORDIC India Pvt. Ltd. as Part of Global Expansion Strategy (LINK)
Notice of Annual General Meeting 2023 (LINK)
Evaxion Biotech
Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform (LINK)
Expres2ion
Expres2ion announces final outcome of its rights issue (LINK)
Fluoguide
No news the past week
Genmab
No news the past week
Gubra
No news the past week
Initiator Pharma
No news the past week
IO Biotech
No news the past week
Pila Pharma
No News the past week
Saniona
No news the past week
Scandion Oncology
No news past week
SynAct Pharma
SynAct Pharma publishes annual report 2022 (LINK)
ViroGates
No news past week
Zealand Pharma
Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference (LINK)
Y-mAbs Therapeutics
No news past week
2cureX
2CUREX PRESENTS PRELIMINARY Q1 2023 COMMERCIAL RESULTS (LINK)
2CUREX HAS RECEIVED A GRANT FROM THE INNOVATION FUND DENMARK TO SUPPORT CLINICAL DEVELOPMENT OF A NOVEL INDITREAT PRODUCT (LINK)
SELECTED CASES
SHARE PRICE DEVELOPMENTS
Evaxion Biotech A/S became the best performing Danish biotech company last week with a 36% increase after Evaxion and Pennsylvania State University published preclinical data validating their AI-platform. At the opposite end of the spectrum ViroGates A/S fell 17%. Since the start of the year, most of the companies have been under pressure, while especially Saniona AB, Curasight and Fluoguide AB have performed well. Saniona has made a strong comeback after several years of downturns. This follows a possible approval for the company’s weight loss lead-candidate in Mexcio, which could generate royalties for Saniona.
Read more about Fluoguide: The unique cancer treatment of the future – Today’s investment
